We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current TRDA market cap is 703.5M. The company's latest EPS is USD -0.1786 and P/E is -104.93.
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Revenue | 25.26M | 18.17M | 43.74M | 41.85M | 59.12M |
| Operating Income | -5.78M | -16.3M | 14.01M | 4.91M | 21.11M |
| Net Income | -6.67M | -25.93M | 35.46M | -9.54M | 23.5M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 0 | 0 | 129.01M |
| Operating Income | -51.13M | -97.25M | -3.16M |
| Net Income | -51.16M | -94.62M | -6.69M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Total Assets | 475.57M | 493.98M | 485.03M | 469.19M | 510.84M |
| Total Liabilities | 245.96M | 287.08M | 238.37M | 226.83M | 241.48M |
| Total Equity | 229.61M | 206.91M | 246.66M | 242.36M | 269.37M |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 305.83M | 252.06M | 469.19M |
| Total Liabilities | 7.12M | 39.5M | 226.83M |
| Total Equity | 298.72M | 212.55M | 242.36M |
| Quarter End | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |||
| Operating | 203.4M | 168.31M | 143.82M | 139.8M | -25.52M |
| Investing | -40.44M | -153.7M | -157.44M | -138.4M | 26.15M |
| Financing | 19.54M | 19.98M | 20.35M | 21.04M | 206k |
| Year End 31 December 2023 | 2021 | 2022 | 2023 |
|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | |
| Operating | -50.86M | -93.79M | 139.8M |
| Investing | -4.58M | -148.65M | -138.4M |
| Financing | 307.46M | 479k | 21.04M |
| Market Cap | 703.5M |
| Price to Earnings Ratio | -104.93 |
| Price to Sales Ratio | 5.44 |
| Price to Cash Ratio | 10.37 |
| Price to Book Ratio | 2.89 |
| Dividend Yield | - |
| Shares Outstanding | 37.42M |
| Average Volume (1 week) | 96.62k |
| Average Volume (1 Month) | 134.89k |
| 52 Week Change | 18.24% |
| 52 Week High | 20.49 |
| 52 Week Low | 10.7501 |
| Spread (Intraday) | 3.43 (18.05%) |
| Company Name | Entrada Therapeutics Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.entradatx.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
